Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation.
Considerable progress has been made in our understanding of the pathophysiology of coronary artery disease (CAD), their acute presentations as acute coronary syndromes (ACS) and the role of LDL cholesterol. In particular there is clear evidence that atherosclerosis is far from being a process that leads to an amorphous flow limiting lesion on an angiogram, but rather involves a complex interplay between the endothelium, inflammatory cells and the coagulation cascade occurring throughout the coronary vascular bed. While a culprit flow limiting lesion may be effectively treated by a drug eluting stent or coronary bypass surgery, this will have little impact on the global molecular processes that determine recurrent plaque instability at non-culprit sites. The search for systemic long term therapy, which is safe and effective and reduces the changes in inflammation, endothelial function and thrombosis that are the hallmark of ACS, has pushed statins to the forefront. A number of recent clinical trials have shown the benefits of early statin therapy in the treatment of ACS. In addition to their effects on LDL cholesterol, statins have a number of properties collectively referred to as pleiotropic effects, which enable them to modulate the adverse biological changes that are associated with ACS. The purpose of this review is to acquaint the reader with the biological changes that accompany ACS, highlight how these pathways may be modulated for clinical benefit by statins and identify potential novel targets for future therapy.
Ray
Kausik K
KK
Cardiovascular Division, Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. kkray@partners.org
Cannon
Christopher P
CP
D000208:Acute Disease; D001777:Blood Coagulation / Q000187:drug effects* / Q000502:physiology; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000188:drug therapy / Q000473:pathology
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors